Munawwar Hussain

Researcher

UAMS

Last publication 2024 Last refreshed 2026-05-16

faculty

6 h-index 13 pubs 93 cited

Research Areas

Links

ORCID

OverviewAI-generated summary

Munawwar Hussain's research focuses on multiple myeloma, investigating clinical outcomes and therapeutic advancements for patients with relapsed or refractory disease. His work includes the study of CAR-T therapy directed at BCMA and the use of bone-modifying agents. Hussain has also examined the corneal toxicity associated with specific treatments like belantamab mafodotin and explored the feasibility of outpatient stem cell transplantation for multiple myeloma patients, identifying risk factors for hospital admission. His recent publications also touch upon the stem cell origin of cancer and its clinical implications for drug and therapy development. Hussain has a collaborative network with several researchers at the University of Arkansas for Medical Sciences, evidenced by multiple shared publications. His scholarship metrics include an h-index of 6, with 13 total publications and 90 total citations.

Metrics

h-index: 6
Publications: 13
Citations: 93

Selected Publications

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)

2 citations DOI OpenAlex
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article (2023)

16 citations DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

2 citations DOI OpenAlex
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy (2022)

21 citations DOI OpenAlex
Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy (2022)

7 citations DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

DOI OpenAlex
Poster: MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022)

14 citations DOI OpenAlex
The use of bone-modifying agents in multiple myeloma (2022)

15 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

13 citations DOI OpenAlex
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

5 citations DOI OpenAlex